Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/118953
Efficacy and safety of Pegylated Interferon-α2b Plus Ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Low response rates and concerns about safety have limited the implementation of treatment for chronic hepatitis C (CHC) in patients with HIV infection. The efficacy and safety of pegylated interferon (peg-IFN) plus ribavirin in HIV-infected patients with CHC were evaluated in a prospective, open-label, multicenter study. Sixty patients with persistently high transaminases, positive HCV-RNA, CD4 count ≥300 cells/µl, and HIVRNA <10,000 copies/ml were included. Patients were given peg-IFN 80-150 µg/week plus ribavirin 800-1200 mg/day. Treatment was scheduled for 24 weeks for genotypes 2/3 and 48 weeks for genotypes 1/4. In an intent- to-treat analysis, 16 (26.7%) patients achieved a sustained virological response (SVR). Twenty patients (33.3%) discontinued treatment prematurely, but only in 10 (16.6%) was discontinuation due to adverse events. Negative predictive values for SVR on the basis of HCV-RNA decline between baseline and week 4 were 100% for 1- and 2-log10 fall, and positive predictive values were 40% and 58.3% for 1- and 2-log10 fall, respectively. CD4 fell by a median of 216 cells during treatment, but no HIV-associated complications occurred. In conclusion, treatment with peg-IFN alfa-2b plus ribavirin is safe and clears RNA-HCV in about one-quarter of HIV-infected patients with CHC. Efforts should be focused on optimizing management of side effects and counseling to improve adherence and to keep patients on treatment. Assessment of HCV-RNA at week 4 may help guide early therapeutic decision making.
Matèries (anglès)
Citació
Citació
SANTÍN CEREZALES, Miguel, SHAW PERUJO, Evelyn, GARCIA, Maria jose, DELEJIDO, Antonio, RODRÍGUEZ DE CASTRO, Eduardo, ROTA ROCA, Rosa, ALTÉS, Jordi, BAGUENA, Francisco, VALERO, Silvia, SALA, Montserrat, CASANOVA RITUERTO, Aurora, HCV/HIV-01 Study Team. Efficacy and safety of Pegylated Interferon-α2b Plus Ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. _Aids Research and Human Retroviruses_. 2006. Vol. 22, núm. 4, pàgs. 315-320. [consulta: 11 de abril de 2026]. ISSN: 0889-2229. [Disponible a: https://hdl.handle.net/2445/118953]